United States Food and Drug Administration (USFDA) has completed an inspection at Lupin’s Injectable facility in Nagpur, India. The inspection of the facility was carried out from June 10 to June 13, 2024, and concluded with zero 483 observations.
Earlier, the company had entered into Business Transfer Agreement (BTA) with Lupin Life Sciences (LLSL) wholly owned subsidiary of the Company, to carve out, its trade generics business in India, as a going concern, on a slump sale basis.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
